Early trial targets 'Undruggable' cancer mutation
NCT ID NCT06818812
Summary
This is a first-in-human study to test the safety and initial effectiveness of a new drug called INCB186748. It is for adults with advanced or metastatic solid tumors that have a specific genetic change called a KRAS G12D mutation. The main goals are to find a safe dose and see how the body handles the drug, both alone and in combination with other cancer therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Jefferson University Hospitals
Philadelphia, Pennsylvania, 19107, United States
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Sarah Cannon Research Institue At Healthone
Denver, Colorado, 80218, United States
-
Scri Oncology Partners
Nashville, Tennessee, 37203, United States
-
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, 21287-7049, United States
-
UCLA Healthcare Hematology-Oncology
Santa Monica, California, 90404, United States
Conditions
Explore the condition pages connected to this study.